ClinicalTrials.gg
CompletedNCT02994550Updated Aug 4, 2022

Influence of FSH/LH Ratio in Controlled Ovarian Stimulation

An Early Phase 1 interventional study of FSH/LH in Sub-Fertility, sponsored by Hospital de Cruces. Completed. Open to female participants aged 35 Years to 40 Years. Per ClinicalTrials.gov, last updated 2022-08-04.

Sponsored by Hospital de Cruces · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
447
Allocation
Non-randomized
Ages
35 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies testing Follicle Stimulating Hormone in Infertility — 1 open to participants now, 1 under way, none of them phase 3. Follicle Stimulating Hormone · Infertility.

Enrollment
3rd of 12
447 · median 239
Started
2017
the only one that year
Phase 1
2 of 12
1 open now
Registered
10th of 12
by date
Lead sponsor
1 of 12
Hospital de Cruces

Among the 12 studies testing Follicle Stimulating Hormone in Infertility, this one is the 3rd largest by enrollment, is the only one that started in 2017, is one of 2 in phase 1, and was the 10th registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

1 of the 12 studies testing Follicle Stimulating Hormone in Infertility is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Follicle Stimulating Hormone

Follicle Stimulating Hormone: first FDA approval 1997 (GONAL-F). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 35 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing Follicle Stimulating Hormone in Infertility, or all of them as a file.
02

Study summary

The aim of this study is to compare different FSH/LH ratios in controlled ovarian stimulation

03

Conditions studied

  • Sub-Fertility

Browse trials for

Keywords

  • FSH
  • LH
  • IVF
04

Who can participate

Ages eligible
35 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing IVF cycles in Cruces University Hospital.
  • Signed IVF and cryopreservation .
  • Age >35 and \<40 years.
  • FSH levels \<10 mIU/ml.

Exclusion criteria

Exclusion Criteria:

  • When inclusion criteria are not fulfilled
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
447 participants (actual)

Study arms

  • Experimental
    FSH/LH 2/1

    dose: 300IU FSHrec and 150IU LHrec

    Drug: FSH/LH

  • Experimental
    FSH/LH 4/1

    dose: 300IU FSHrec and 75IU LHrec

    Drug: FSH/LH

Interventions

06

What researchers measure

Primary outcomes

  1. Pregnancy achievement

    To report our results in terms of pregnancy per embryo transfer

    Time frame: 3 months after drug administration

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Dec 2017, 11 months.

Of 28 phase 1 interventional studies under Infertility, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 38. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2016
First posted
Dec 16, 2016
StartActual
Jan 2017
Primary completionActual
Dec 2017
CompletionActual
Jan 2018
Last update
Aug 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02994550
Lead sponsor
Hospital de Cruces
Responsible party
Antonia Exposito (PhD, Hospital de Cruces) — Principal investigator
First posted
Dec 16, 2016
Start date
Jan 2017
Primary completion
Dec 2017
Completion
Jan 2018
Last update
Aug 4, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follicle Stimulating Hormone

Start the discussion